Extracellular Vesicle Hydrogels for Sustained Tumor Antigen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EV therapies suffer from poor tissue retention, limiting their efficacy due to the administration of EVs in solution form, which leads to inefficient delivery and processing of tumor antigens.
Innovation Solution
Development of hydrogels covalently linked to extracellular vesicles using click chemistry, incorporating a glycan moiety, with polymers like polyethylene glycol, to enhance tissue retention and facilitate the processing and presentation of tumor antigens by dendritic cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If EVs are administered in solution form, then they can be easily delivered systemically, but their tissue retention is poor
Solution Approach 1:
The patent combines EVs with hydrogel polymers to create a composite material system. The hydrogel serves as a scaffold that physically retains EVs at the injection site while maintaining a hydrated environment conducive to EV function. This composite approach allows both easy delivery (via injectable hydrogel formulation) and improved tissue retention (through the gel matrix entrapment).
Solution Approach 2:
The hydrogel forms a flexible, three-dimensional network that acts as a retentive matrix. This gel structure can be injected as a liquid that then gels in situ, providing a flexible containment environment that holds EVs locally without requiring rigid structures, thus maintaining ease of administration while improving retention.
2Quantity of substance
If high numbers of EVs are administered to compensate for poor retention, then the initial dose is increased, but the overall efficacy is dampened
Solution Approach 1:
The hydrogel formulation enables sustained, continuous release of EVs over time rather than a single bolus that is rapidly cleared. This continuous action maintains therapeutic EV levels at the target site, improving overall efficacy without requiring excessively high initial doses. The gel matrix provides a reservoir that releases EVs progressively.
Solution Approach 2:
The hydrogel is prepared and administered in advance to establish a retained EV reservoir at the target site before therapeutic action is needed. This preliminary placement ensures that EVs are already positioned and retained locally, ready to exert their therapeutic effect continuously rather than requiring repeated high-dose administrations.
3Duration of action of stationary object
If multiple doses are administered to improve retention, then the treatment frequency is increased, but the efficacy is still limited
Solution Approach 1:
The hydrogel provides a sustained-release platform that maintains EV presence at the target site over an extended period through a single administration. This continuous action over time replaces the need for multiple discrete dosing events, achieving both prolonged duration of action and improved efficacy by maintaining consistent local EV concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogels provide sustained delivery of EVs, allowing for prolonged antigen presentation and induction of tumor-specific CD8+ T cell responses, enhancing therapeutic efficacy against cancer.
Implementation Method 1
the plurality of extracellular vesicles are covalently linked to the polymer by click chemistry (such as azide-alkyne click chemistry, tetrazine-norbornene click chemistry, tetrazine-cyclooctene click chemistry, or maleimide-thiol click chemistry)
Implementation Method 2
hydrogels that include a plurality of extracellular vesicles covalently linked to a polymer
Data Source
AI summary
Hydrogels including a plurality of extracellular vesicles covalently linked to a polymer, wherein the covalent link includes a glycan moiety, are provided. Methods of making and using the hydrogels, for example, for treating or inhibiting cancer, are also provided.